PEDF PAT13D9AT Antibody
Description
Introduction to PEDF PAT13D9AT Antibody
The PEDF PAT13D9AT Antibody is a mouse monoclonal antibody (IgG1κ isotype) specifically targeting Pigment Epithelium-Derived Factor (PEDF), a 50 kDa glycoprotein with neurotrophic, anti-angiogenic, and anti-tumorigenic properties . This antibody is widely used in research to detect and study PEDF’s role in diseases such as cancer, diabetic retinopathy, and fibrotic disorders .
Role of PEDF and Antibody Utility
PEDF inhibits angiogenesis by inducing apoptosis in endothelial cells and suppressing pro-angiogenic factors like VEGF and FGF-2 . The PAT13D9AT antibody aids in studying these mechanisms by detecting PEDF expression in:
-
Fibrotic Tissues: PEDF inhibits TGF-β1-induced fibroblast activation by upregulating PPAR-γ, reducing collagen-I and α-SMA production .
-
Immune Regulation: PEDF enhances regulatory T-cell (Treg) function, mitigating autoimmune responses in diseases like dry eye syndrome (DED) .
-
Cancer and Angiogenesis: PEDF’s anti-tumor effects are linked to its collagen-binding domain (D255, D257, D299), which is critical for inhibiting neovascularization .
Experimental Validation
The antibody has been validated for:
Anti-Fibrotic and Anti-Angiogenic Potential
PEDF’s role in pulmonary fibrosis has been demonstrated using gene-delivery models, where PEDF overexpression reduces bleomycin-induced fibrosis by suppressing fibroblast activation . The PAT13D9AT antibody could facilitate biomarker studies to monitor PEDF levels in clinical trials.
Immune Modulation
In murine models of DED, PEDF enhances Treg suppressive function by upregulating FOXP3, CTLA-4, and IL-10 expression . The antibody may help elucidate PEDF’s interaction with Treg cells in autoimmune diseases.
Comparative Analysis with Other PEDF Antibodies
Product Specs
Pigment epithelium-derived factor,PEDF, Serpin-F1, SerpinF1, EPC-1, EPC1, PIG35.
PEDF antibody was purified by protein-A affinity chromatography.
PAT13D9AT.
Anti-human PEDF mAb, is derived from hybridization of mouse F0 myeloma cells with spleen cells from BALB/c mice immunized with a recombinant human PEDF protein 20-418 amino acids purified from E. coli.
Mouse IgG1 heavy chain and κ light chain.
Product Science Overview
The Mouse Anti Human Pigment Epithelium-Derived Factor (PEDF) Clone PAT13D9AT is a monoclonal antibody specifically designed to target and bind to the human PEDF protein. PEDF, also known as Serpin F1, is a 50,000 dalton glycoprotein that exhibits neurotrophic, anti-angiogenic, and anti-tumorigenic properties . This protein is secreted by various tissues throughout the body and plays a crucial role in inhibiting angiogenesis by inducing apoptosis in proliferating endothelial cells .
The Mouse Anti Human PEDF mAb is produced through the hybridization of mouse F0 myeloma cells with spleen cells from BALB/c mice that have been immunized with a recombinant human PEDF protein . The recombinant PEDF protein, consisting of amino acids 20-418, is purified from Escherichia coli (E. coli) . The resulting monoclonal antibody is then purified using protein-A affinity chromatography to ensure high specificity and reactivity .
PEDF’s anti-angiogenic action is primarily mediated through the induction of apoptosis in endothelial cells and the inhibition of angiogenic factors such as VEGF and FGF-2 . Additionally, PEDF has neuro-protective effects by suppressing neuronal apoptosis induced by peroxide, glutamate, or other neurotoxins . The recognition of a lipase-linked cell membrane receptor for PEDF (PEDF-R) that binds to PEDF with high affinity has further elucidated the underlying mechanisms of this pluripotent serpin .
The Mouse Anti Human PEDF Clone PAT13D9AT antibody has been tested and validated for use in various applications, including ELISA, Western blot analysis, and immunocytochemistry/immunofluorescence (ICC/IF) . Its unique range of activities makes it a potential therapeutic agent for treating vasculature-related neurodegenerative diseases such as age-related macular degeneration (AMD) and proliferative diabetic retinopathy (PDR) . Additionally, PEDF has potential applications in treating various angiogenesis-related diseases, including certain cancers .
